1. Home
  2. RUN vs MIRM Comparison

RUN vs MIRM Comparison

Compare RUN & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunrun Inc.

RUN

Sunrun Inc.

HOLD

Current Price

$18.42

Market Cap

4.7B

Sector

Miscellaneous

ML Signal

HOLD

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$79.92

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RUN
MIRM
Founded
2007
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.7B
4.2B
IPO Year
2015
2019

Fundamental Metrics

Financial Performance
Metric
RUN
MIRM
Price
$18.42
$79.92
Analyst Decision
Buy
Strong Buy
Analyst Count
18
11
Target Price
$20.63
$92.45
AVG Volume (30 Days)
5.5M
811.9K
Earning Date
11-06-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,316,656,000.00
$471,794,000.00
Revenue This Year
$18.76
$53.78
Revenue Next Year
$5.70
$19.91
P/E Ratio
N/A
N/A
Revenue Growth
13.79
53.66
52 Week Low
$5.38
$36.88
52 Week High
$22.44
$82.58

Technical Indicators

Market Signals
Indicator
RUN
MIRM
Relative Strength Index (RSI) 47.23 62.33
Support Level $16.89 $77.99
Resistance Level $20.71 $82.58
Average True Range (ATR) 0.99 3.21
MACD 0.10 1.03
Stochastic Oscillator 37.79 83.25

Price Performance

Historical Comparison
RUN
MIRM

About RUN Sunrun Inc.

Sunrun is engaged in the design, development, installation, sale, ownership, and maintenance of residential solar energy systems in the United States. The company acquires customers directly and through relationships with various solar and strategic partners. The solar systems are constructed by Sunrun or by Sunrun's partners and are owned by the company. Sunrun's customers typically enter into 20- to 25-year agreements to utilize its solar energy system. The company also sells solar energy systems and products, such as panels and racking, and solar leads generated to customers.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Share on Social Networks: